Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.
| Company | Change | P/E (TTM) |
|---|---|---|
ARIAAriad Pharmaceuticals Inc. | +2.33% | - |
ARRYArray BioPharma Inc. | +2.46% | - |
ONTYOncothyreon Inc. | +0.90% | - |
GSKGlaxoSmithKline PLC ADR | +1.74% | 7.68 |
PFEPfizer Inc. | +0.91% | 24.23 |
CERUCerulean Pharma Inc. | +1.17% | - |
Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial...
| Q4 2015 Estimate Trends | |
|---|---|
| Current: | $-1.87 |
| 1 month ago: | $-1.95 |
| 3 months ago: | $-1.85 |
| Q1 2016 Estimate Trends | |
|---|---|
| Current: | $-1.99 |
| 1 month ago: | $-2.14 |
| 3 months ago: | $-2.01 |
| Dec 2015 | 5-quarter trend | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Growth | -29.89% | | ||||||||||
| Sales or Revenue | - | |||||||||||
| Sales or Revenue Growth | - | |||||||||||
| EBITDA | -61.89 M | | ||||||||||
| 2015 | 5-year trend | |||||||||||
| Net Income Growth | -68.55% | | ||||||||||
| Sales or Revenue | - | |||||||||||
| Sales or Revenue Growth | - | |||||||||||
| EBITDA | -239.50 M | |